We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ardelyx's financial performance into perspective.
+ 0.80 (+6.15%)
4:00 PM ET on Feb 23, 2017
Delayed at least 20 minutes.
Feb 17, 2017
Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
Feb 15, 2017
Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
Feb 15, 2017 at 8:30 AM ET
Ardelyx Clinical Update
Jan 10, 2017 at 3:30 PM PT
J.P. Morgan 35th Annual Healthcare Conference
Nov 7, 2016 at 4:05 PM ET
Ardelyx Third Quarter 2016 Earnings Call